Noxopharm Ltd. (AU:NOX) has released an update.
Noxopharm Limited, a pioneering biotech firm, has bolstered its financial flexibility by issuing a $500,000 convertible note to a long-term investor, providing additional funding for its innovative projects. This strategic move allows Noxopharm to pursue capital management opportunities with reduced time constraints, while offering the investor attractive conversion terms and unlisted options.
For further insights into AU:NOX stock, check out TipRanks’ Stock Analysis page.